Overview
- 4 inspections across 4 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2017-05-26.
At a glance
Inspections
4
Sites
4
Observations
0
Career since
Oct 2016
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Boehringer Ingelheim Pharma GmbH and Co. KG | 26 May 2017 | Human Drugs | On file |
| Boehringer Ingelheim Fremont, Inc. | 4 Apr 2017 | Human Drugs | On file |
| KBI Biopharma, Inc. | 9 Dec 2016 | Human Drugs | On file |
| Bristol-Myers Squibb Company | 21 Oct 2016 | Human Drugs |
Sites inspected
Boehringer Ingelheim Pharma GmbH and Co. KGBiberach An Der Ris, Germany1 insp.
Boehringer Ingelheim Fremont, Inc.Fremont, United States1 insp.
KBI Biopharma, Inc.Boulder, United States1 insp.
Bristol-Myers Squibb CompanyDevens, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Richard Ledwidge1 shared
Christopher D Downey1 shared
Yanming An1 shared
Ephrem T Hunde1 shared
Maria I Cruz-Fisher1 shared
Kristin M Abaonza1 shared
Diane L Raccasi1 shared
Kathleen R Jones1 shared
Veronica Fuentes1 shared
Anh Lac1 shared
Full investigator report
Get the verbatim findings behind Monica M Commerford's inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site